Imunon, Inc. (CLSN) Bundle
Who's buying Imunon, Inc. (CLSN) and why the market is buzzing: institutional investors like DRW Securities, LLC, Riverview Capital Advisers, LLC and The Vanguard Group, Inc. boosted positions through September 30, 2025-DRW alone holds 55,027 shares (a 2.51% stake)-even as institutional ownership is reported at 7.2% (down from 226.7% in June 2025), while the general public still holds roughly 91.9% of shares; notable moves include Riverview's accumulation to 34,364 shares (a staggering 3,730% increase), The Vanguard Group's rise to 23,301 shares (+59.6%), Geode's growth to 19,812 shares (+78.6%), and SBI Securities' cut of 12,839 shares (a 92.29% decrease)-with 16 of 17 funds increasing exposure and CEO Michael Tardugno among insiders holding meaningful stakes, these concrete shifts in ownership and percentages paint a vivid picture of confidence, retail enthusiasm and strategic repositioning that demand a closer look in the sections that follow.
Imunon, Inc. (CLSN) - Who Invests in Imunon, Inc. (CLSN) and Why?
Imunon, Inc. (CLSN) has drawn a mix of institutional and individual backers as it advances through clinical stages. Institutional buying activity through September 30, 2025, alongside concentrated insider stakes and broad retail ownership, frames a distinctive investor profile driven by belief in the company's clinical pipeline, near-term catalysts and balance-sheet management.- Institutional investors-including DRW Securities, LLC, Riverview Capital Advisers, LLC, and The Vanguard Group, Inc.-have increased holdings as of 9/30/2025, signaling institutional confidence in clinical progress and financial stability.
- CEO Michael Tardugno and other insiders hold meaningful personal stakes, aligning management incentives with shareholder value creation.
- The general public (retail) owns approximately 91.9% of shares, indicating widespread retail interest and speculative appetite despite CLSN's clinical-stage status.
- Sixteen of seventeen reporting funds expanded exposure to CLSN during the period, a strong directional indicator of positive institutional sentiment.
| Investor | Shares Held | % of Outstanding | Notable Change (to 9/30/2025) |
|---|---|---|---|
| DRW Securities, LLC | 55,027 | 2.51% | Increased position |
| Riverview Capital Advisers, LLC | Reported (institutional stake) | - | Increased exposure |
| The Vanguard Group, Inc. | Reported (institutional stake) | - | Increased exposure |
| CEO Michael Tardugno (insider) | Significant insider holdings | Material insider stake | No major sell-offs reported |
| Retail / General Public | Approx. 2,014,593 shares | 91.9% | Largest single ownership cohort |
| Total estimated outstanding shares | ~2,192,147 | 100% | Derived from DRW position disclosure |
- Why institutions are increasing exposure: belief in near-term clinical readouts, favorable risk-reward for a clinical-stage biotech, and opportunistic valuation/float dynamics.
- Why insiders retain stakes: alignment with long-term value creation, confidence in development strategy and potential licensing/partnership upside.
- Why retail dominance matters: tight public float dynamics can amplify price moves on clinical news; high retail ownership can sustain momentum but also increase volatility.
Imunon, Inc. (CLSN) - Institutional Ownership and Major Shareholders of Imunon, Inc. (CLSN)
As of September 30, 2025 institutional investors collectively held 7.2% of Imunon, Inc. (CLSN) shares, a marked decline from 226.7% reported in June 2025, indicating a substantial reduction in reported institutional ownership over the quarter.
- Aggregate institutional ownership (Sep 30, 2025): 7.2% (vs. 226.7% in Jun 2025)
- Largest institutional holder: DRW Securities, LLC - maintained a ~2.51% stake
- Notable accumulations: Riverview Capital Advisers, The Vanguard Group, Geode Capital Management
- Significant reduction: SBI Securities Co., Ltd. materially trimmed its position
| Major Holder | Shares Held | % of Outstanding Stock | Quarterly % Change | Notes |
|---|---|---|---|---|
| DRW Securities, LLC | +55,027 shares (increase) | 2.51% | 0% (no change in % terms) | Largest institutional stake; position increased in share count |
| Riverview Capital Advisers, LLC | 34,364 shares | 1.79% | +3,730% | Massive quarter-over-quarter accumulation |
| The Vanguard Group, Inc. | 23,301 shares | N/A | +59.6% | Notable increase suggesting growing confidence |
| Geode Capital Management, LLC | 19,812 shares | N/A | +78.6% | Strong bullish accumulation |
| SBI Securities Co., Ltd. | -12,839 shares (reduced) | N/A | -92.29% | Substantial reduction, likely portfolio reallocation |
Context on Imunon, Inc. (CLSN): Imunon, Inc. (CLSN): History, Ownership, Mission, How It Works & Makes Money
Imunon, Inc. (CLSN) - Key Investors and Their Impact on Imunon, Inc. (CLSN)
Imunon, Inc. (CLSN) institutional ownership trends through 9/30/2025 show concentrated bets by several key holders that shape liquidity, market perception, and potential runway for clinical development.- DRW Securities, LLC - 55,027 shares (2.51%): a sizable position signaling institutional confidence in CLSN's clinical programs and near-term catalysts.
- Riverview Capital Advisers, LLC - 34,364 shares (1.79%): position grew by 3,730% quarter-over-quarter, indicating a dramatic directional bet on growth potential.
- The Vanguard Group, Inc. - 23,301 shares (1.12%): increased 59.6% from prior quarter, reflecting expanding passive/index or ETF exposure to CLSN.
- Geode Capital Management, LLC - 19,812 shares (0.76%): up 78.6% quarter-over-quarter, consistent with a bullish reallocation into CLSN.
- SBI Securities Co., Ltd. - reduction of 12,839 shares (92.29% decrease): a sharp withdrawal that may reduce short-term demand and increase share price sensitivity to news.
| Investor | Shares Held | % of Shares Outstanding | Quarterly Change (%) | Impact |
|---|---|---|---|---|
| DRW Securities, LLC | 55,027 | 2.51% | - | Large stake, signals institutional conviction in clinical pipeline |
| Riverview Capital Advisers, LLC | 34,364 | 1.79% | +3,730% | Rapid accumulation; high conviction/speculative trade |
| The Vanguard Group, Inc. | 23,301 | 1.12% | +59.6% | Growing passive/ETF-related ownership |
| Geode Capital Management, LLC | 19,812 | 0.76% | +78.6% | Notable increase; indicates bullish outlook |
| SBI Securities Co., Ltd. | 1,064 | 0.05% | -92.29% | Massive cut; reduces a prior source of demand |
- Aggregate behavior: 16 of 17 institutional funds increased exposure quarter-over-quarter - a collective signal of positive sentiment toward CLSN's prospects and potential upcoming clinical or corporate catalysts.
- Market implications: Concentrated increases by active managers (Riverview, Geode, DRW) can amplify price moves around news; large passive inflows (Vanguard) support baseline demand; outsized reductions (SBI) can create short-term volatility.
Imunon, Inc. (CLSN) - Market Impact and Investor Sentiment
- Institutional snapshot: 16 of 17 tracked funds increased exposure to Imunon, Inc. (CLSN), signaling a broadly positive institutional reassessment.
- Retail ownership remains substantial, reflecting strong public confidence in CLSN's clinical-stage upside despite inherent development risk.
- Institutional ownership reported at 226.7% in June 2025 fell to 7.2% by September 2025, indicating large portfolio rebalancing or market-driven adjustments.
- Insider alignment: substantial insider ownership - including CEO Michael Tardugno's significant stake - helps align management incentives with outside shareholders.
- Notable fund moves: Riverview Capital Advisers, LLC increased holdings by 3,730%, while SBI Securities Co., Ltd. reduced theirs by 92.29% - both moves likely affecting short-term sentiment.
| Holder | Reported Jun 2025 Holdings | Reported Sep 2025 Holdings | % Change |
|---|---|---|---|
| Riverview Capital Advisers, LLC | 10,000 shares | 373,000 shares | +3,730% |
| SBI Securities Co., Ltd. | 100,000 shares | 7,710 shares | -92.29% |
| Aggregate 17 Funds (count) | 17 tracked funds - 1, increased exposure not specified | 17 tracked funds - 16 increased exposure | +94.1% of funds increased |
| Institutional Ownership (company-wide) | 226.7% (Jun 2025) | 7.2% (Sep 2025) | -219.5 ppt |
| Retail Ownership (company-wide) | - | Significant (majority retail concentration) | - |
| Insider Ownership (notable) | CEO Michael Tardugno: significant stake | Management & insiders: substantial combined ownership | - |
- Market impact: The concentration of retail holders can amplify volatility around catalysts (trial readouts, licensing news) while rising institutional buys from select active managers can provide stability and validation.
- Sentiment drivers: Large percentage swings in singular institutional holders (both big increases and steep reductions) create mixed signals - endorsement by aggressive buyers like Riverview contrasts with exits by firms such as SBI Securities.
- Governance signal: High insider ownership, including the CEO, tends to be viewed positively by many investors as it aligns risk-reward between management and shareholders.
Imunon, Inc. (CLSN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Imunon, Inc. (CLSN) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Imunon, Inc. (CLSN)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Imunon, Inc. (CLSN)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.